|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi T, Saikawa Y and Kitagawa Y:
Gastric cancer: Current status of diagnosis and treatment. Cancers
(Basel). 5:48–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berardi R, Scartozzi M, Romagnoli E,
Antognoli S and Cascinu S: Gastric cancer treatment: A systematic
review. Oncol Rep. 11:911–916. 2004.PubMed/NCBI
|
|
6
|
Kienast T and Heinz A: Dopamine and the
diseased brain. CNS Neurol Disord Drug Targets. 5:109–131. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fuxe K, Manger P, Genedani S and Agnati L:
The nigrostriatal DA pathway and Parkinson's disease. J Neural
Transm Suppl. 71–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schneier FR, Liebowitz MR, Abi-Dargham A,
Zea-Ponce Y, Lin SH and Laruelle M: Low dopamine D(2) receptor
binding potential in social phobia. Am J Psychiatry. 157:457–459.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hentges ST and Low MJ: Ovarian dependence
for pituitary tumorigenesis in D2 dopamine receptor-deficient mice.
Endocrinology. 143:4536–4543. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wood DF, Johnston JM and Johnston DG:
Dopamine, the dopamine D2 receptor and pituitary tumours. Clin
Endocrinol (Oxf). 35:455–466. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J, Zhu S, Kozono D, Ng K, Futalan D,
Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, et al:
Genome-wide shRNA screen revealed integrated mitogenic signaling
between dopamine receptor D2 (DRD2) and epidermal growth factor
receptor (EGFR) in glioblastoma. Oncotarget. 5:882–893. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Senogles SE: D2 dopamine receptor-mediated
antiproliferation in a small cell lung cancer cell line, NCI-H69.
Anticancer Drugs. 18:801–807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clague J, Cinciripini P, Blalock J, Wu X
and Hudmon KS: The D2 dopamine receptor gene and nicotine
dependence among bladder cancer patients and controls. Behav Genet.
40:49–58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Basu B, Sarkar C, Chakroborty D, Ganguly
S, Shome S, Dasgupta PS and Basu S: D1 and D2 dopamine
receptor-mediated inhibition of activated normal T cell
proliferation is lost in jurkat T leukemic cells. J Biol Chem.
285:27026–27032. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sachlos E, Risueno RM, Laronde S,
Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn
A, Graham M, et al: Identification of drugs including a dopamine
receptor antagonist that selectively target cancer stem cells.
Cell. 149:1284–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li K, Dan Z and Nie YQ: Gastric cancer
stem cells in gastric carcinogenesis, progression, prevention and
treatment. World J Gastroenterol. 20:5420–5426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abdullah LN and Chow EK: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li F, Tiede B, Massagué J and Kang Y:
Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res.
17:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget. Jun
30–2016.(Epub ahead of print).
|
|
20
|
Byun HJ, Lee JH, Kim BR, Kang S, Dong SM,
Park MS, Lee SH, Park SH and Rho SB: Anti-angiogenic effects of
thioridazine involving the FAK-mTOR pathway. Microvasc Res.
84:227–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rho SB, Kim BR and Kang S: A gene
signature-based approach identifies thioridazine as an inhibitor of
phosphatidylinositol-3′-kinase (PI3K)/AKT pathway in ovarian cancer
cells. Gynecol Oncol. 120:121–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M,
Tan Z, Ding Q, Zhang L, Lu J, et al: Thioridazine, an antipsychotic
drug, elicits potent antitumor effects in gastric cancer. Oncol
Rep. 31:2107–2114. 2014.PubMed/NCBI
|
|
23
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levi E, Sochacki P, Khoury N, Patel BB and
Majumdar AP: Cancer stem cells in Helicobacter pylori infection and
aging: Implications for gastric carcinogenesis. World J
Gastrointest Pathophysiol. 5:366–372. 2014.PubMed/NCBI
|
